Latest News and Press Releases

Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan ...

K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...

The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering MARIETTA, Ga., Aug. 26, 2022 ...

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management...

Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year...

Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA, Ga., July 27, 2022 (GLOBE...

MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report...

Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational...

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) --...

Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee Stock Purchase Plan MARIETTA, Ga., June 07,...